BORDEAUX, France, July 29, 2024 – TreeFrog Therapeutics, the French biotech company advancing a pipeline of regenerative medicine cell therapies announces a new member to the executive committee, Dr. Peter Andersen, as Chief Research & Development Officer.
“I am delighted that Peter is joining TreeFrog Therapeutics. Attracting a talented expert of his caliber is demonstrative of the potential of TreeFrog to bring the promise of regenerative medicine into the here and now. It is the right time to reinforce the research team and bring in a new Chief Research & Development Officer as we look to advance our pipeline in Parkinson’s disease and acute liver failure, while adding new programs and putting new research collaborations in place”. Frédéric Desdouits, CEO of TreeFrog Therapeutics.
Peter brings over 15 years of expertise in pluripotent stem cell biology and regenerative medicine, acquired from both academic and industry settings. During his tenure at the Johns Hopkins University, Baltimore, Peter co-founded Vita Therapeutics, Inc., a pioneering biotechnology company dedicated to developing regenerative iPSC-based cell-therapies for degenerative neuromuscular disorders. Serving as Chief Scientific Officer at Vita for five years, Peter oversaw all aspects of research and development, including pre-clinical and pipeline advancements. Peter is a Danish citizen and holds a PhD in developmental biology from Copenhagen University and maintains an adjunct professor appointment at the Johns Hopkins School of Medicine. He has authored over forty scientific papers and patents.
“We are entering into the renaissance of regenerative iPSC-derived therapies and TreeFrog Therapeutics is at the forefront. There are still major challenges to get allogeneic cell therapies to patients with unmet needs where existing pharmacological treatments often provide symptomatic or episodic relief only. Treefrog’s proprietary technology, C-Stem™, has the potential to overcome the major obstacles of scalability and production of cell therapies of high quality, at the right scale, efficiently. It is a very exciting time to join the company and I look forward to leading the R&D efforts and teams in place”. Dr. Peter Andersen, Chief Research & Development Officer, TreeFrog Therapeutics.
-Ends-
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry — producing and differentiating cells of quality at unprecedented scale, cost-effectively. To realize their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players in other areas. In the last 3 years, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. In 2022, the company opened technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of the C-StemTM platform and establish strategic alliances with leading academic, biotech and industry players.
MEDIA CONTACTS
Rachel MOONEY
Chief Communications Officer
Rachel.mooney@treefrog.fr